

# DCVNM COVID-19 Committee: updates

2nd TC with members and observers

29th June 2020 12 pm CET

# World Economic Forum Vaccine summit, 26th June 2020, 6.30 pm CET



03

## Multi-stakeholder Perspectives on COVID-19 Vaccine Capacity and MANAGE-COV



### Perspective on Building Additional Capacity



Sai Prasad  
President  
Developing Countries Vaccine Manufacturers Network

04

## Multi-stakeholder Perspectives on COVID-19 Vaccine Capacity and MANAGE-COV



### Perspectives on Securing Manufacturing Capacity



Adar Poonawalla  
CEO  
Serum Institute of India



Krishna Ella  
Chairman and Managing Director  
Bharat Biotech



Morena Makhoana  
CEO  
Biovac



Raul Machado-Neto  
Director, Institutional Strategy  
Instituto Butantan

05

## Multi-stakeholder Perspectives on COVID-19 Vaccine Capacity and MANAGE-COV



### Organizing a Vaccine Marketplace and Review of Procurement (COVAX) Initiative



Seth Berkley  
CEO  
GAVI, the Vaccine Alliance



Richard Hatchett  
CEO  
Coalition for Epidemic Preparedness Innovations

06

## Multi-stakeholder Perspectives on COVID-19 Vaccine Capacity and MANAGE-COV



### The Need for "Push" and "Pull" Funding Mechanisms



Saul Walker  
Deputy Director, Department for International Development  
United Kingdom

07

## Multi-stakeholder Perspectives on COVID-19 Vaccine Capacity and MANAGE-COV



### Financing Strategy and Footprint in Life Sciences



Sriviya Jagannathan  
Life Science Sector Head  
International Finance Corporation



Subir Basak  
Senior Industry Specialist  
International Finance Corporation

08

## Multi-stakeholder Perspectives on COVID-19 Vaccine Capacity and MANAGE-COV



### Government Viewpoints




K. Vijay Raghavan  
Principle Scientific Advisor  
India



Shigeru Arizumi  
Deputy Director General,  
Ministry of Finance  
Japan

## COVID-19 - Financing Structures for Vaccine Manufacturing


COVAX Facility can be complemented through an IFC-led financing and technical assistance platform to lever grant funding in scaling up manufacturing





# ACT-ACCELERATOR

Total investment needed  
**US\$ 31.3 BILLION**



## Health Systems Connector



Strengthening health systems to make sure essential COVID-19 tools reach the people who need them



The ACT-Accelerator will deliver new tools for the whole world.




World Health Organization

ACTaccelerator  
ACCESS TO COVID-19 TOOLS


ACT Now, ACT Together to end COVID-19

## Required investments

A total of US\$31.3 billion is needed for the work of the ACT Diagnostics, Therapeutics and Vaccines pillars. These needs have been developed through pillar-specific scenarios and assumptions that are detailed in their respective plans and investment cases. The total needs have been calculated over a 12 months period for the Therapeutics and Diagnostics pillars, and 18 months for the Vaccines pillar.



The 'immediate needs' represent the critical investments required within the next six months to meet the ACT-Accelerator targets. These needs can be broken down into the major activities of each pillar as follows:




**NOTE:** assuming safe and effective vaccines are developed in the near future, ACT's current estimate for the delivery of 2 billion doses of vaccine by the end of 2021 is up to US\$18.1 billion, with 950 million of those doses procured by self-financing high and upper middle-income countries through the COVAX Facility. These numbers will be updated as understanding of the technology that the successful vaccine candidates will be based on, and the number of doses required to protect people from COVID-19, improves.

26 June 2020

<https://www.who.int/publications/m/item/act-accelerator-investment-case>

These generous pledges represent 11% of the total investment needed for ACT Diagnostics, Therapeutics and Vaccines:



In summary, the diagnostic, therapeutic and vaccine pillars of the ACT-Accelerator will need an additional US\$27.9 billion, including US\$13.7 billion to cover immediate needs (i.e. \$17.1 B required - \$3.4 B pledged). Fortunately, there is growing recognition of the benefits of collaborating through ACT, our most promising hope of a successful global effort to end the virus.

The collage consists of three screenshots from a YouTube browser window. The top-left screenshot shows the 'Global Goal: Unite for Our Future | The Concert' video player with a black background and white text. The top-right screenshot shows a live stream of a video conference with four participants: Boris Johnson, Ursula von der Leyen, Angela Merkel, and Donald Trump. The bottom screenshot shows a 3D virtual stadium with the word 'REPAIR' on the field. The browser's address bar and taskbar are visible across the top and bottom of the images.

- Saturday afternoon the European Commission led Global Goal: Unite for our Future Summit again brought together a tremendous line-up of world leaders in support of the ACT Accelerator and the COVID Response.
- The Summit mobilized US\$1.5 billion in new cash grants and US\$5.4 billion in new loans & guarantees,
- totalling US\$6.9 billion in new funding.

# **CEPI query to DCVMN nomination of at least two representatives to the COVAX technical working group**

- DCVMN Covid committee Chairperson, Adriansjah Azhari, (viral vaccines large-scale manufacturing expertise)
- Sinovac, Weining Meng, COVID-19 vaccine development (clinical and manufacturing expertise, cf. <https://www.clinicaltrialsarena.com/news/sinovac-coronavac-data/>)
- Butantan, Ricardo Palacios,, COVID-19 vaccine development (clinical expertise, cf. Ethics of controlled human infection to address COVID-19, Science 22 May 2020: Vol. 368, Issue 6493, pp. 832-834, cf. <https://science.sciencemag.org/content/368/6493/832> )